| abstract |
Treatment of PKC-β or Nuclear Factor Kappa B (NFKB) mediated diseases, in particular: (i) diabetes or complications thereof, (ii) ischemia/reperfusion injury and complications thereof, (iii) atherosclerosis, (iv) restenosis, (v) tumour growth, or (vi) undesired or uncontrolled angiogenesis by administering an effective amount of (i) a polyunsaturated fatty acid (PUFA) including an oxa and/or thia substitution at either or both of the β- or γ-position; (ii) a PUFA covalently coupled to an amino acid; (iii) a polyunsaturated nitroalkene or nitroalkyne; (iv) a n-3 PUFA; or (v) a n-6 PUFA, optionally in combination with an Angiotensin-Converting Enzyme (ACE) inhibitor. A pharmaceutical composition including an ACE inhibitor and (i) a PUFA including an oxa and/or thia substitution at either or both of the β- or γ-position; (ii) a PUFA covalently coupled to an amino acid; (iii) a polyunsaturated nitroalkene or nitroalkyne; (iv) a n-2 PUFA; or (v) a n-6 PUFA. |